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Non-melanoma skin cancer (NMSC) is the most common form of cancer in the US and its incidence is increasing. The
current standard of care is visual inspection by physicians and/or dermatologists, followed by skin biopsy and pathologic
confirmation. We have investigated the use of in vivo fluorescence imaging using fluorocoxib A as a molecular probe for
early detection and assessment of skin tumors in mouse models of NMSC. Fluorocoxib A targets the cyclooxygenase-2
(COX-2) enzyme that is preferentially expressed by inflamed and tumor tissue, and therefore has potential to be an effective
broadly active molecular biomarker for cancer detection. We tested the sensitivity of fluorocoxib A in a BCC allograft SCID
hairless mouse model using a wide-field fluorescence imaging system. Subcutaneous allografts comprised of 1000 BCC
cellsweredetectable abovebackground. TheseBCCallograftmicewere imagedover timeanda linearcorrelation (R2=0.8)
between tumor volume and fluorocoxib A signal levels was observed. We also tested fluorocoxib A in a genetically
engineeredspontaneousBCCmousemodel (Ptch1+/−K14-Cre-ER2p53fl/fl),wheresequential imagingof thesameanimals
over time demonstrated that early, microscopic lesions (100 μm size) developed into visible macroscopic tumor masses
over 11 to17days.Overall, formacroscopic tumors, the sensitivitywas88%and thespecificitywas100%.Formicroscopic
tumors, the sensitivity was 85% and specificity was 56%. These results demonstrate the potential of fluorocoxib A as an
in vivo imaging agent for early detection, margin delineation and guided biopsies of NMSCs.
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Skin malignancies are traditionally classified as melanoma vs.
nonmelanoma skin cancer (NMSC). NMSC is mainly comprised
of two types: i) basal cell carcinoma (BCC), which is the most
common type (~80% of all NMSC), evolves from basal epithelial
cells in the epidermis and rarely metastasizes – but can invade the
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a cancer of squamous epithelial cells, is less abundant (~20%ofNMSC)
but more aggressive. NMSC is the most common malignancy in the
United States [1] as well as other reported countries [2]. NMSC is
underestimated and often excluded from cancer statistics [3], although
its prevalence more than doubles that of all other cancers combined [4]
and its incidence continues to rise [1]. Despite a low mortality rate, the
morbidity and cost associated with NMSC places it as the fifth most
expensive cancer to treat overall in theMedicare population [1,5]. Early
detection of skin cancer is the best way to improve patient outcome and
reduce related costs, although it remains difficult in practice.
The current standard of care for skin cancer screening is visual
inspection by primary care physicians or dermatologists, by the naked eye
or using a dermascope, which heavily relies onmedical experience. Other
noninvasive systems have been investigated for skin cancer detection and
classification, such as near-infrared reflectance confocal microscopes
[6,7], which lackmolecular specificity. Other approaches include the use
of lesion-associated markers that can be fluorescently detected, such as
protoporphyrin-IX (PpIX) detection after light exposure on areas
incubated with the photodynamic therapy drug, 5-aminolevulinic acid
(ALA) [8–11]. However, phototoxicity precludes its wider use for
screening/diagnostic purposes on sun-exposed areas of the skin.
In order to specifically target a cancer-associatedmarker,Marnett and
coworkers recently developed an indomethacin-based fluorescent probe
that they called fluorocoxib A (LM-4777) [12], which specifically binds
cyclooxygenase-2 (COX-2), an enzyme that is preferentially expressed
in inflamed and neoplastic tissue. COX-2 is the inducible cyclooxy-
genase isoenzyme and is induced by cytokines, mitogens and growth
factors. It has been found to be abundantly over-expressed both in
inflamed and cancerous tissues of the colon [13], prostate [14], breast
[15], pancreas [16], lung [17], and skin [18–21]. Therefore, fluorocoxib
A has potential to be an effective molecular probe for early cancer
detection as a marker of both inflammation and malignancy.
Most BCC tumors are characterized by an aberrant expression of
genes involved in the hedgehog-signaling pathway, often caused by
mutations induced by UV light [22]. One of these affected genes,
Ptch1, is an inhibitor of hedgehog signaling and is the cause of Basal
Cell Nevus Syndrome (BCNS), a rare disease in which over 90% of
the patients develop multiple BCCs. Epstein, Tang and colleagues
have demonstrated that celecoxib, a selective COX-2 inhibitor, was
able to decrease the severity of carcinogenesis in a BCNS mouse
model (PF14 mice), and in BCNS patients in a 60-patient clinical
trial [23]. These findings corroborated previous studies that linked
COX-2 activation to the development of skin cancer [19].
Here we report detection of non-melanoma skin cancer (NMSC) in
mice by in vivo fluorescence imaging using the fluorocoxib A probe.
Materials and Methods
Animals
Animal work was carried out according to the guidelines for animal
care of the National Institutes of Health, Stanford University and the
Children’s Hospital Oakland Research Institute (CHORI).
Spontaneous BCC Mouse Model. Ptch1+/− K14-Cre-ER2 p53fl/fl
(PF14)mice were injected with 100 μl of tamoxifen (1mg/ml) for three
consecutive days. At eight weeks of age, mice were given 4 GY of
ionizing radiation. Typically, microscopic BCCs develop in this model
at 5mo of age and visible BCCs develop between 7 to 9 months as
previously described [22]. This served as our spontaneous BCC/NMSCmousemodel for our molecular imaging experiments. The dorsal hair of
the mouse was removed using Nair (Church & Dwight Co., Ewing,
NJ) 24 hours before injection of the molecular probe for imaging.
BCC Allograft Mouse Model. SCID Hairless Outbred (SHO)
mice were purchased from Charles River Laboratories (Wilmington,
MA). BCC allografts were generated by subcutaneous injection of
BCC cells into the flanks of SCID hairless mice. The single
suspension of BCC cells were either from a previously established
BCC cell line or isolated from primary tumors of the PF14 mouse.
For the primary tumor allografts, spontaneous tumors from PF14
mice were sliced into small pieces and incubated in 0.5% collagenase
(Gibco #17100-017) solution for 1 hour at 37°C. Cells were further
dissociated by pipetting and passed through a 70 μm cell strainer.
Cells were collected by centrifugation and resuspended at 20,000 cell/μl.
Equal amounts of cell suspensions were mixed with ice-cold Matrigel
(BD, Franklin Lakes, NJ) and injected intradermally (ID) 100 μl
(106 cells) into the lower flanks (left and right) of SHO mice. Also,
different amounts of cells (100, 500, 1000, and 1,000, 5,000,
10,000) were subcutaneously injected in different regions of the
lower back area of SHO mice to analyze the sensitivity (number of
cells) of this detection approach.
The allografts from a BCC cell line were generated using a
previously immortalized cell line (BSZ) from PF14 tumors [24]. BSZ
cells were maintained in BSZ medium, prepared with 154-CF
medium (Cascade Biologics, Portland, OR) containing 1% penicillin
and streptomycin, 2% heat-inactivated fetal bovine serum (FBS) and
chelexed with Chelex Resin Chelating Ion Exchange Resin (Biorad
Laboratories, Hercules CA) and calcium chloride (0.2 mM). After
trypsinization BSZ cells were resuspended in PBS and 106 cells were
subcutaneously injected into the flanks of SHO mice [25].
Tumor location was recorded using a digital camera and tumor
growth was recorded over time with caliper measurement. Tumor
volume is calculated using the formula L*W2/2 [26].
Systemic Administration of Molecular Probe
The systemic solution of 1 mg/kg fluorocoxib A was formulated as
described by Uddin et al. [12], consisting of DMSO (16%), EtOH
(33%), propylene glycol (17%) and sterile PBS (34%). A fluorocoxib
A solution (60 μl) was injected retro-orbitally (ro) into mice that had
been anaesthetized with 2% isofluorane.
In Vivo Fluorescence Imaging
One week prior to imaging, mice were fed low-fluorescent chow
(Harlan Laboratories, Indianapolis, IN). Anesthetized (2% isofluorane)
mice were imaged at different time points after injection of fluorocoxib
A (30 min, 3 h, 5 h, 7 h, 25 h) with the CRi Maestro (Caliper Life
Sciences, Alameda, CA) in vivo imaging system using the auto-exposure
mode. Fluorocoxib A fluorescence signals were monitored at 10 nm
windows from500 to 800 nmusing an excitation filter (503 to 555 nm)
and a long-pass emission filter (580 nm). The fluorocoxib A
fluorescence spectrum of the skin of each mouse strain was obtained
by unmixing the autofluorescence, previously obtained from a non-
injected P14mouse or SHOmouse. The protocol generatedwas used to
analyze the acquired image data. Fluorescence average signal (counts per
second per mm2) was quantified over a region of interest (roi),
corresponding to tumors, using Maestro software.
In a co-injection experiment, a LiCor800-equivalent probe (LM-
5516) was used as a negative probe (non-COX-2 binding probe) in
combination with fluorocoxib A. The two fluorescence spectra were
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Maestro software. Autofluorescence was unmixed similarly as described
above. Unmixed images are pseudo-colored red for fluorocoxib A (LM-
4777) and blue for LM-5516.
Histopathologic Analysis of Tissue Samples
Mice were euthanized at the appropriate endpoint after imaging,
considering tumor stage and size. The mice were visually inspected and
macroscopically-detectable tumors were collected for further analysis.
The skin of the mouse was also compared with the fluorescence image
obtained with Maestro, and regions of the skin presenting fluorescence
are considered as possible microscopic tumor sites while regions of skin
not presenting any fluorescence signal under a certain threshold were
considered as possible negative controls.
After removal of tissue, samples were immersed in a 2%
formaldehyde, 0.2% glutaraldehyde in PBS solution for at least one
hour. The fixative was aspirated and sample washed with PBS twice
(PBS aspirated after each washing). The sample was stained using a β-
gal staining kit (Roche, cat #: 11828673001) overnight. The staining
solution was then removed and the sample washed with a 3% DMSO
in PBS solution two times (solution aspirated after each washing),
washed with 70% ethanol three times (ethanol aspirated after each
washing), and left in 70% ethanol. Samples were processed for
paraffin block embedding, sectioning, and hemotoxylin and eosin
(H&E) staining (Redwood Dermatopathology, Santa Rosa, CA) [22].Immunohistochemistry
Tissues were collected in 10% buffered formalin and were
embedded in paraffin for preparation as 5-μm tissue sections. All
tissue sections were subjected to antigen retrieval in 0.1 mM Citric
acid for 8 minutes, and were treated in 10% H2O2 for 10 minutes to
block endogenous peroxidase activity.BA
ETumor 1
Tumor 2
0 h 3 h
Figure 1. Specific targeting of tumor with fluorocoxib A and its im
fluorescence imaging of BCC allograft mice after co-injection of Flu
Time sequence is (A) 0 hours (B) 3 hours (C) 5 hours (D) 7 hours post-
image below (A). The red signal represents LM-4777 and the blue sig
tumor 1 and 2 at each time point for LM-4777 and LM-5516.Immunhistochemical staining was performed using an affinity
purified primary rabbit anti-mouse COX-2 antibody (Cayman
Chemical, # 160126; 1 μg/ml), which is detected using the ImmPRESS
HRP anti Rabbit Ig (Peroxidase) Kit (Vector Laboratories, Burlingame,
CA), and visualized with 3,3′ diaminobenzidine tetrahydrochloride
(DAB) (Invitrogen, Carlsbad, CA). Sections were counterstained with
hematoxylin (Thermo Fisher Scientific, Waltham, MA).
Results and Discussion
In Vivo Detection of NMSC with the Fluorocoxib A Probe
We used the BCC allograft model for establishing the in vivo imaging
procedure of NMSC with fluorocoxib A. Figure 1 shows time-lapse
in vivo fluorescence imaging of allograft mice after co-injection of
fluorocoxibA (LM-4777) and LiCor800-equivalent (LM-5516) probes.
We observed that fluorocoxib A specifically bound to the two tumor
sites in Figure 1, B–D. From Figure 1E, fluorocoxib A fluorescence
signal was determined to peak at 3 to 5 hours post-injection. The non-
targeting LM-5516 shows minimal accumulation in the tumor sites.
This demonstrates the targeting specificity of the fluorocoxib A probe to
skin tumors, and establishes that the optimal timeframe for imaging is 3 to 5
h post-injection. This corroborates well with previous reports on
fluorocoxib A [12], and we therefore choose the 3 h post-injection
timepoint for our in vivo fluorescence imaging experiments.
In Vivo Fluorocoxib A Signal Level Experiments with the
Allograft Mouse Model
We tested the sensitivity of fluorocoxib A in the BCC allograft mouse
model. Different numbers of BCC cells (100, 500, 1000 and 1000,
5000, 10,000) were subcutaneously injected into SCID hairless mice.
The mice were then subsequently injected with fluorocoxib A, retro-
orbitally. Sites with 1000 BCC cells, or greater, were consistently
detectable above background.C D
5 h 7 h
aging timecourse in the BCC allograft model. Time-lapse in vivo
orocoxib A (LM-4777) and LiCor800-equivalent (LM-5516) probes.
injection, where the allograft mouse is oriented as in the brightfield
nal represents LM-5516. (E) Total unmixed fluorescence signal of
A B
Figure 2. Linear relationship between fluorescence signal from fluorocoxib A and tumor volume in allograft models. Graphs of tumor size
vs in vivo fluorescence signal for BCC allograft mice. (A) Allografts from BCC cell line (7 tumors from 4 mice). (B) Allografts from primary
tumors (13 tumors from 7 mice).
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tumor size was investigated with two types of BCC allograft mice, one
derived from a BCC cell line and one derived from primary tumors of
the P14 mouse model. The fluorescence signal corresponding to each
tumor mass is plotted in Figure 2, A and B, respectively. Allografts
from the BCC cell line exhibit a better linear fit compared to the
primary tumor derived allografts (R2 = 0.80 versus 0.69) which is
most likely due to the cell population being more homogenous.
In Vivo Detection of NMSC in PF14 Spontaneous Mouse Model
P14 mice [22] that spontaneously develop BCC and SCC were
imaged 3 h after systemic administration of fluorocoxib A via
retroorbital injection. Threshold levels were set after unmixing the
fluorescence spectra of the probe from the background, which mainly
consists of autofluorescence of the skin. Then, tissue regions that were
above threshold were harvested and processed for histologic analysis.A
C
Macroscopic
SCC
Dorsal Skin
A
B
D
CEF
Figure 3. In vivo detection of macroscopic and microscopic NMSCs
image (red), overlayed with brightfield image (grey), taken with Ma
unmixed image that is thresholded and segmented (red), overlayed
macroscopic SCC, within region A of (A). (D) Histology of microscopVisually discernable tumors are referred to as macroscopic tumors,
while visually indiscernable tumors that look normal, but are later
determined through histopathologic analysis to be small tumors are
referred to as microscopic tumors. Figure 3 shows an in vivo imaging
example and its corresponding representative histology. All the
macroscopic tumors show fluorescence signal, while some other
regions show signals above a threshold (Figure 3B) that visually
present like normal skin. Both macroscopic tumors and potential
microscopic tumor sites, along with control samples (below threshold
signal) were harvested shortly after in vivo imaging. Microscopic
BCCs were confirmed on sites such as region 3 in Figure 3B, through
histologic analysis (Figure 3D), where microscopic tumors down to
100 μm in size could be detected. We have analyzed skin containing
56 macroscopic fluorescent regions, 54 microscopic fluorescent
regions, and 18 non-fluorescent regions (N = 9 mice). The threshold
size for histopathologically confirming microscopic tumors is set toB
D
Microscopic
BCC
in the spontaneous P14 mouse model. (A) Fluorescence unmixed
estro. A–F refer to macroscopic visible tumors. (B) Fluorescence
with brightfield image (grey), taken with Maestro. (C) Histology of
ic BCC, within region 3 of (B). The size of the scale bars is 100 μm.
BA C
Figure 4. Sequential in vivo imaging of P14 mice shows development of macroscopic tumors. This is an overlay of the unmixed
fluorescence image (thresholded) and color photograph of the same mouse corresponding to (A) Day 1, (B) Day 17, and (C) Day 27.
Between Day 1 and Day 17, 3 macroscopic tumors developed from suspect ROIs (region of interest; potential microscopic tumor sites).
Between Day 17 and Day 27, 7 macroscopic tumors emerge from suspect ROIs. The arrows follow tumor growth and corresponding
fluorocoxib A signal of one region.
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specificity is 100%. For microscopic tumors, the sensitivity is 85%
and specificity is 56%. Some false-negatives were attributed to areas
that are adjacent to high-signal macroscopic tumors, which couldFigure 5. Immunohistochemical analysis of COX-2 expression. Two
taken from the same tissue block. Microscope images were taken at
P14 mouse model. (B) Immunohistochemistry of same tissue block as
BCC in the allograft mouse model. (D) Immunohistochemistry from s
showing COX-2 expressing cells.have overshadowed weak microscopic tumor signal. The lower
specificity for microscopic tumors may be due to false positives
resulting from interrogating a small subset of the imaged tissue region
through histopathology. The sensitivity and specificity are dependentpairs of histology and immunohistochemistry slide images each
4x magnification. (A) Histology image of a microscopic BCC in the
(A). (C) Histology image of a microscopic (indiscernible) metastatic
ame tissue block as (C). (E) 40× magnification of a sub-area of (D)
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unmixing stage, and the histologic threshold size that is set to
determine microscopic tumors. This is especially the case with late
stage transgenic P14 mice, which have numerous tumors developing
throughout the skin surface. For human NMSCs, the development of
tumors are more spatially separated, and therefore will be better suited
for sensitive, early detection.
Sequential In vivo Imaging of P14 Spontaneous Mouse Model
to Track Tumor Development
We performed sequential in vivo imaging of the spontaneous tumor
mice over time in order to track fluorescence signal and its correlation
with tumor development. Figure 4 shows one mouse that was imaged
over a period of four weeks. We observed 3 macroscopic tumors
emerging from previous suspect ‘regions of interest’ (ROIs) between
Day 1 and Day 17. The ROIs for each imaging time point were
determined as regions emitting fluorescence signal above threshold. An
additional 7macroscopic tumors developed from suspect ROIs between
Day 17 and Day 27. Overall, three mice were sequentially imaged,
where 13 suspect ROIs (potential microscopic tumor sites) became
macroscopic tumors while 3 ROIs did not develop into macroscopic
tumors. This shows that fluorocoxib A signal is a good indicator for
ROIs (that could already be microscopic tumor sites) that have a high
probability of developing into macroscopic tumors in the future. This
has implications for early detection and treatment that can be
complemented with signal tracking of ROIs.
Immunohistochemical Detection of COX-2 Expression
Histolopathological classification and immunohistochemical analysis
of COX-2 expression, shown in Figure 5, A and B, were performed on
serial tissue sections from a microscopic BCC from the P14 spontaneous
mouse model. COX-2 was predominantly expressed by cells within the
dermal layer above the tumor. Figure 5, C and D show histologic and
immunohistochemical analysis of a microscopic BCC on the back of the
allograft mouse model. As shown in Figure 5, B and D, COX-2 was
mainly expressed by stromal cells within the dermis and hypodermis
overlying the tumors, withminimal expression of COX-2 in the epithelial
cells of the tumormass itself. As shown inFigure 5E, COX-2-positive cells
exhibit a macrophage morphology, with predominantly cytoplasmic and
perinuclear staining, a pattern consistent with the intracellular location of
the COX-2 enzyme. These expression patterns are consistent with
previous studies in human BCCs [19], colorectal tumors [27], and
subdermal mammary tumor xenografts (unpublished observations)
reporting COX-2 expression predominantly by infiltrating macrophages.
One group has localized COX-2 expression to CD68-positive
macrophages using dual-labeling immunofluorescence, and reported
their proximity to capillaries [27]. These observations have led to the
suggestion that COX-2 positive macrophages play a role in early tumor
progression via the promotion of angiogenesis [27]. These reports along
with our imaging data, show the potential of early detection of NMSC
through sensitive and specific detection of COX-2 expressing cells.Conclusion
We have demonstrated in vivo detection of NMSC after systemic
administration of fluorocoxib A that targets COX-2. Sensitive
fluorescence imaging and analysis allows for detection of microscopic
tumors that are visually undetectable otherwise. These results demon-
strate the potential of fluorocoxib A as an effective in vivo imaging agent
for early detection, margin delineation and guided biopsies of NMSCs.Acknowledgements
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